Company InformationGenomenon was founded on January 2014. The company is based in Ann Arbor, MI, USA . The number of employees in Genomenon is less than 50. Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making.
Here is how Genomenon describes itself: "The world’s most comprehensive source of genomic evidence. We help you identify critical biomarkers for NGS. Download Mastermind today!"
Funding & investorsGenomenon has received 6 rounds of venture funding. The total funding amount is around $11.1M. Last venture funding round was $5.3M, announced on March, 2021.
- VitalizeVC (Micro vc)
- IrishAngels (Angel group)
- Kaufman Financial Group
- Mike Klein (Angel)
- National Institutes of Health (Entrepreneurship program)
- Michigan Angel Fund (Angel group)
- InvestMichigan (Government office)
- Three Leaf Ventures (Venture capital)
- Invest Detroit (Micro vc)
- Atain (Angel group)
- BroadOak Capital Partners (Investment bank)
- Green Park & Golf Ventures (Venture capital)
- Invest Detroit Ventures (Micro vc)
- Michigan Rise
- Contact us if you are interested to see all 16 investors
Similar Companies [beta]
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Software
- Active Investors in Wellness
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Software Startups
- Best Funded Wellness Startups
Genomenon - Blog
- Don’t Miss Variants: Upgrading From the Cited Variants Reference to the Mastermind API
- Accelerating Rare Disease Diagnosis with Genomic Data
- OUR RARE STORIES | Rare Disease Day 2022
- Guest Blog: Don’t Forget Morgan – Elle’s Story
- Rapid Variant Interpretation with the Mastermind Relevancy Score
- Top Three Benefits of Locus-Specific Patient Databases for Rare Disease
In this blog, chief technology officer Steve Schwartz describes the limitations of the Mastermind Cited Variants Reference (CVR) that affect genomic analyses, and how the integration of Mastermind’s API can help surmount them. The Mastermind Cited Variants Reference (CVR) is an open-access file, available in VCF (variant call format) or CSV (comma-separated values) formats for … Continue readingThe post Don’t Miss Variants: Upgrading From the Cited Variants Reference to the Mastermind API appeared first on Genomenon.
Genomenon CEO, Mike Klein, shares how Mastermind’s new Disease-Specific Curated Content is helping clinicians discover new treatment options for rare diseases. Disease-Specific Curated Content Shortens the Diagnostic Odyssey Genomenon has developed a new feature in the Mastermind Genomic Search Engine that enables faster and more accurate diagnosis of rare diseases. Disease-Specific Curated Content gives clinical … Continue readingThe post Accelerating Rare Disease Diagnosis with Genomic Data appeared first on Genomenon.
In honor of Rare Disease Day February 28, 2022, we are excited to present Genomenon’s “Our Rare Stories” Live Blog, where we will be compiling articles, informative webinars, press releases, and other compelling resources that all play a part in highlighting the inspiration for our mission—patient stories. Monday, FEBRUARY 28, 2022 “Our Rare Stories” has … Continue readingThe post OUR RARE STORIES | Rare Disease Day 2022 appeared first on Genomenon.
In June of 2016, I sat with my husband in a doctor’s office awaiting the results of genetic testing that had been performed on our daughter, Elle. Elle was five at the time and had struggled with global developmental delay, particularly speech and language development, since birth. When she had begun to experience atypical seizures, … Continue readingThe post Guest Blog: Don’t Forget Morgan – Elle’s Story appeared first on Genomenon.
The key to rapid and accurate literature curation for clinical interpretation and therapeutic discovery is standardizing and optimizing the review process. The Mastermind Genomic Search Engine meets this need with a collection of sophisticated algorithms that prioritize search results by relevance. This proprietary process is called the Mastermind Relevancy Score. Why is the Mastermind Relevancy … Continue readingThe post Rapid Variant Interpretation with the Mastermind Relevancy Score appeared first on Genomenon.
In a recent webinar, Genomenon’s chief scientific officer Dr. Mark Kiel was joined by Dr. Gus Khursigara, VP of Medical Affairs and Clinical Strategy at Inozyme Pharma. This blog explores three key benefits of locus-specific patient databases (or Patient Landscapes), and how they are helping Inozyme better understand and target rare diseases. 1. Patient Landscapes … Continue readingThe post Top Three Benefits of Locus-Specific Patient Databases for Rare Disease appeared first on Genomenon.